A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Trial ID or NCT#

NCT05795699

Status

recruiting iconRECRUITING

Purpose

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Official Title

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Charles C. Lin, MD
Charles C. Lin, MD
Cornea specialist, Cataract specialist
Clinical Associate Professor, Ophthalmology

Contact us to find out if this trial is right for you.

Contact

Director, Clinical Operations
919-433-1600

SEND MESSAGE

View on ClinicalTrials.gov